Study on BMS-986393 CAR T Cell Therapy for Adults with Relapsed or Refractory Multiple Myeloma

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT06297226

Provider View

This clinical trial is testing a new CAR T cell therapy, BMS-986393, to see if it is safe and effective for adults with multiple myeloma that has returned or not responded to previous treatments.

Patient Parameters

Program Overview

The goal of this study is to determine how well a new treatment, BMS-986393, works and how safe it is for patients with multiple myeloma, a type of blood cancer, that has either come back after treatment or has not responded to other treatments.

Eligibility Criteria

Inclusion Criteria

  • Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria.
  • Received at least 3 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, and at least 3 prior lines of therapy (LOT).
  • Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria.
  • Participants must have measurable disease during screening.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria

  • Active or history of central nervous system involvement with MM.
  • Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis.
  • Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.